STAREE
STAtin Therapy for Reducing Events in the Elderly
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 9,971 healthy adults aged 70 years or over, atorvastatin 40 mg was compared with placebo on disability-free survival and major cardiovascular events.
N
9.971
Design
Double-blind, placebo-controlled RCT, 1:1, recruited through Australian general practice, average follow-up about 6 years planned, time-to-first-event analyses for each co-primary endpoint
Endpunkt
Co-primary — (1) disability-free survival, defined as survival free of dementia and persistent physical disability; (2) major cardiovascular events (cardiovascular death, non-fatal myocardial infarction or stroke; registry definition also lists coronary revascularisation)